58 results about "Endotoxic shock" patented technology

A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

Method for the treatment of endotoxic shock in mammals. The use of vasoactive intestinal peptide (VIP) and peptide activating hypofissiary adenylate cyclase (PACAP) is described in the treatment of endotoxic shock in mammals. These substances inhibit the production of tumor necrosis factor (TNF) and interleukin 6 (IL-6).

Provided are methods of attenuating release of a proinflammatory cytokine from a mammalian cell. Also provided are methods of inhibiting or treating an inflammatory cytokine cascade in a mammal. Further provided are methods of treating a mammal at risk for or undergoing sepsis, septicemia, and/or endotoxic shock. Additionally provided are methods of attenuating NO release from a mammalian cell. Also provided are methods of attenuating NO production in a mammal at risk for, or having, a disorder mediated by excessive NO production.

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting substrate metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction on an organism. The sequence of the polypeptide is Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu which is a brand new sequence (D-Pyr is D-type pyridine alanine, D-Cys isD-type cysteine, and Bip is diphenyl alanine). The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate of an endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

The invention discloses application of parthenolide as a platelet-activating factor (PAF) inhibitor. The parthenolide can be used as a safe PAF antagonist to be applied to treatment, auxiliary treatment and prevention of diseases such as thrombus, atherosclerosis, ischemic cardio-vascular disease, cerebral ischemia, acute pancreatitis, endotoxic shock, asthma, hepatic fibrosis and hepatocirrhosis, injury of nerve, gastrointestinal ulcer and necrosis, psoriasis, systemic lupus erythematosus and acquired immune deficiency syndrome related to platelet-activating factor.

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting substrate metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction to an organism. The sequence of the polypeptide is Pro-Arg-Cys-(D-Bip)-(D-Arg)-Gly-Glu which is a brand new sequence (D-Bip is D-type diphenyl alanine, and D-Arg is D-type arginine). The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate of an endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

Cyano and carboxy derivatives of substituted styrenes are inhibitors of tumor necrosis factor α, nuclear factor κB, and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3,3-bis-(3,4-dimethoxyphenyl)acrylonitrile.

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.

This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction of levels of inflammatory mediators.

Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.

The invention relates to anti-inflammation effect and application of an immuno-regulatory molecule Rhbdd3, in particular to protein 3 (namely Rhbdd3) or Rhbdd3 coding sequence having an rhomboid structure domain and application of promoter or inhibitor in preparation of drug used for regulating and controlling dendritic cell activation and/or inflammatory factor level or a reagent box, and further relates to application and an application method of the above substance in resisting infection and treating chronic inflammatory diseases caused by infection and corresponding drug, drug combination or reagent box. The immuno-regulator molecule can be used for inhibiting activation of infected dendritic cells and excessive generation of inflammatory factors, increasing survival rate and survival time of organisms in endotoxic shock and protecting visceral organs like lung after being infected from inflammatory damage or can be used for immunoregulation, and has wide application prospect.

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction on an organism. The sequence of the polypeptide is Pro-Arg-(D-Cys)-Bip-Arg-Gly-Glu (Bip is D-type diphenyl alanine, D-Cys is D-type cysteine), which is a brand new sequence. The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate ofan endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

The invention discloses a compound of a single sugar cluster and a heterozygous sugar cluster, which are shown in formula (I), wherein the definition of a substituent group in the compound of the formula (I) is disclosed in detail in the specification. In addition, the invention also discloses a preparation method and a pharmaceutical composition of the compound. The compound has adhesion resistance and a protecting function on endotoxic shock.

The invention relates to the field of medicaments, in particular to a polypeptide for inhibiting matrix metalloproteinase-9 and tumor necrosis factor kallikrein and reducing destroy on an organism by acute inflammatory reaction. A sequence of the polypeptide is Pro-(D-Pyr)-(D-Cys)-Bip-(D-Cys)-Gly-Glu and is a brand new sequence, wherein Bip is biphenyl alanine, D-Pyr is D-type pyridine alanine, and D-cys is D-type cysteine; the activities of the matrix metalloproteinase-9 and the tumor necrosis factor kallikrein can be inhibited in vitro at the level of 1 micromole; the survival rate of mice undergoing endotoxic shock is increased during an in-vivo test; and the polypeptide has a potential novel medicament development value.